Safety Profile
Known Safety Concerns
- Contributes to total caffeine load -- check extract caffeine content
- Cardiovascular effects at high combined caffeine doses
- May lower blood glucose -- relevant for diabetics
- Pregnancy: limit total caffeine to <200 mg/day
Contraindications
- Contributes to total caffeine load -- check extract caffeine content
- Cardiovascular effects at high combined caffeine doses
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Coffee extract concentrates the bioactive compounds from coffee beans including caffeine, chlorogenic acids, and diterpenes. Caffeine content must be checked carefully — extracts range from low-caffeine to very high-caffeine preparations. Contributes significantly to total daily caffeine when combined with other stimulants. Chlorogenic acids in green coffee bean extract have glucose-lowering properties.
Biological and Chemical Classification
- Scientific Name
- Coffea arabica / robusta bean extract
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- Contributes to total caffeine load -- check extract caffeine content
- Cardiovascular effects at high combined caffeine doses
- May lower blood glucose -- relevant for diabetics
- Pregnancy: limit total caffeine to <200 mg/day
The available scientific evidence for Coffee Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 12:45
Evidence Distribution
-
Observational / other LOW evidence YELLOWKinetics of dissolution and computational modeling of calcium oxalate monohydrate crystals in the presence of aqueous coffee bioactive extract compounds. ↗Khattab ET et al.. Kinetics of dissolution and computational modeling of calcium oxalate monohydrate crystals in the presence of aqueous coffee bioactive extract compounds.. Sci Rep. 2026. PMID:41871889.PMID 41871889 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41871889/
-
Observational / other LOW evidence YELLOWStructural Insights and Metabolic Profiles of Oxidized Green Coffee Extract, and Its Impact on Obesity and Gut Microbiota in High-Fat Diet-Fed Mice. ↗He J et al.. Structural Insights and Metabolic Profiles of Oxidized Green Coffee Extract, and Its Impact on Obesity and Gut Microbiota in High-Fat Diet-Fed Mice.. Nutrients. 2026. PMID:41754155.PMID 41754155 ↗Journal NutrientsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41754155/
-
Observational / other LOW evidence YELLOWPolymer-lipid hybrid nanoparticles incorporating green coffee extract: enhancing treatment for hepatic steatosis and fibrosis through metabolomic insights. ↗Uriostegui-Campos MA et al.. Polymer-lipid hybrid nanoparticles incorporating green coffee extract: enhancing treatment for hepatic steatosis and fibrosis through metabolomic insights.. RSC Adv. 2025. PMID:41323711.PMID 41323711 ↗Journal RSC AdvYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41323711/
-
Observational / other LOW evidence YELLOWSystematic Review of the Effects of Plant-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities Such as Obesity, Metabolic Syndrome,… ↗Jurek JM et al.. Systematic Review of the Effects of Plant-Based Foods on Metabolic Outcomes in Adults with MASLD and Comorbidities Such as Obesity, Metabolic Syndrome, and Type 2 Diabetes.. Nutrients. 2025. PMID:41010543.PMID 41010543 ↗Journal NutrientsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41010543/
-
Observational / other LOW evidence YELLOWCoffea arabica Extracts and Metabolites with Potential Inhibitory Activity of the Major Enzymes in Bothrops asper Venom. ↗Pu00e1ez E et al.. Coffea arabica Extracts and Metabolites with Potential Inhibitory Activity of the Major Enzymes in Bothrops asper Venom.. Pharmaceuticals (Basel). 2025. PMID:40872542.PMID 40872542 ↗Journal Pharmaceuticals (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40872542/
-
Observational / other LOW evidence YELLOWEffect of aqueous green coffee extract (Coffea canephora) on the intestinal health of Wistar rats fed with a hypercaloric and hyperlipidic diet. ↗Meneguelli NAS et al.. Effect of aqueous green coffee extract (Coffea canephora) on the intestinal health of Wistar rats fed with a hypercaloric and hyperlipidic diet.. Food Funct. 2025. PMID:40879272.PMID 40879272 ↗Journal Food FunctYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40879272/
-
Observational / other LOW evidence YELLOWTriple-Loaded Nanoemulsions Incorporating Coffee Extract for the Photoprotection of Curcumin and Capsaicin: Experimental and Computational Evaluation. ↗Boonrueang N et al.. Triple-Loaded Nanoemulsions Incorporating Coffee Extract for the Photoprotection of Curcumin and Capsaicin: Experimental and Computational Evaluation.. Pharmaceutics. 2025. PMID:40733134.PMID 40733134 ↗Journal PharmaceuticsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40733134/
-
Observational / other LOW evidence YELLOWSustainable and Green Synthesis of Nano Zero-Valent Iron for Hexavalent Chromium Adsorption. ↗Dinsa M et al.. Sustainable and Green Synthesis of Nano Zero-Valent Iron for Hexavalent Chromium Adsorption.. ACS Omega. 2025. PMID:40687043.PMID 40687043 ↗Journal ACS OmegaYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40687043/
-
Observational / other LOW evidence YELLOWTopical Alternatives for Hair Loss: Beyond the Conventional. ↗Bikash C. Topical Alternatives for Hair Loss: Beyond the Conventional.. Int J Trichology. 2025. PMID:40654553.PMID 40654553 ↗Journal Int J TrichologyYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40654553/
-
Observational / other LOW evidence YELLOWGreen Coffee Extract (Coffea canephora) Administered as Treatment Modulates Hepatic Markers and Attenuates Hepatic Steatosis in Rats Fed a High-Fat Diet. ↗Domiciano do Nascimento M et al.. Green Coffee Extract (Coffea canephora) Administered as Treatment Modulates Hepatic Markers and Attenuates Hepatic Steatosis in Rats Fed a High-Fat Diet.. Mol Nutr Food Res. 2025. PMID:40631586.PMID 40631586 ↗Journal Mol Nutr Food ResYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40631586/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Coffee Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Coffee Extract
A score of 3.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.